Recruiting INTERVENTIONAL NCT05686642

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Safety and Efficacy of LT3001 in Subjects With Acute Ischemic Stroke (AIS)

Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Conditions Acute Ischemic Stroke

Interventions LT3001 Drug:high dose LT3001 Drug:low dose Placebo

Updated 17 times since 2023 Last updated: Apr 29, 2026 Started: Apr 6, 2023 Primary completion: Dec 10, 2026 Completion: Dec 12, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Acute Ischemic Stroke, this trial is actively recruiting participants. The trial is conducted by Shanghai Pharmaceuticals Holding Co., Ltd and has accumulated 17 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

17 versions recorded

May 4, 2026 — Present [daily]

Recruiting

Phase: PHASE2 → None
Sep 2025 — May 2026 [monthly]

Recruiting PHASE2
May 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Feb 2025 — May 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE2

▶ Show 12 earlier versions

Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Jan 2024 — Mar 2024 [monthly]

Recruiting PHASE2
Sep 2023 — Jan 2024 [monthly]

Recruiting PHASE2
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE2
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE2
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE2
May 2023 — Jun 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2023 — May 2023 [monthly]

Not Yet Recruiting PHASE2
Mar 2023 — Apr 2023 [monthly]

Not Yet Recruiting PHASE2
Feb 2023 — Mar 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke

Contact Information

Sponsor contact:

Shanghai Pharmaceuticals Holding Co., Ltd

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baotou, China , Baotou, China , Beijing, China , Beijing, China , Beijing, China , Changchun, China , Chaoyang, China , Daqing, China , Guangzhou, China , Hangzhou, China and 18 more locations